SEC Form 4 · accession 0001209191-15-024642
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore H Stanley
Director
Period of report
Mar 10, 2015
Accepted (ET)
Mar 10, 2015 · 4:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 10, 2015 | M | 3,300 | $7.26 | A | 4,300 | D | |
| Common StockF1 | Mar 10, 2015 | S | 3,300 | $60.0262 | D | 1,000 | D | |
| Common StockF2 | holding | — | — | — | 3,000 | I | by non-profit corporation | |
| Common StockF2 | holding | — | — | — | 5,100 | I | by limited partnership |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.26 | Mar 10, 2015 | M | 3,300 | D | — | May 13, 2023 | Common Stock | 3,300 | 20,000 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The Reporting Person disclaims beneficial ownership of the Securities except to the extent of his pecuriniary interest therein.
- F3The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.